Literature DB >> 7516986

Aberrant expression of membrane cofactor protein and decay-accelerating factor in the endothelium of patients with systemic sclerosis. A possible mechanism of vascular damage.

G T Venneker1, F H van den Hoogen, A M Boerbooms, J D Bos, S S Asghar.   

Abstract

BACKGROUND: One of the main features of systemic sclerosis (SSc) is vascular damage, the mechanism of which is not understood. The aim of this study was to investigate if complement (C) regulatory molecules, membrane cofactor protein (MCP), decay-accelerating factor (DAF), and CD59, which normally protect endothelial cells from damage by autologous C, are absent or down-regulated in vascular endothelium of patients with SSc. A deficiency or persistent down-regulation of the above molecules is likely to render vascular endothelium of these patients susceptible to damage by physiologically or pathologically activated C. From this point of view, expression of MCP, DAF, and CD59 was tested on endothelium of skin of normal subjects and patients with diffuse and limited forms of SSc. EXPERIMENTAL
DESIGN: Punch biopsies of normal skin (N = 11) and lesional and non-lesional skin of patients with diffuse (N = 5) and limited (N = 5) forms of SSc were obtained and serial sections prepared. Immunoperoxidase staining of these sections was carried out using four monoclonal antibodies (MoAbs) directed to different epitopes of DAF, four to different epitopes of MCP, one to CD59 and one to von Willebrand factor. von Willebrand factor served as a marker of endothelial cells. Besides normal skin, lesional skin of systemic lupus erythematosus and several inflammatory and proliferative diseases, described below, served as controls.
RESULTS: The endothelium of normal skin strongly expressed all the three proteins. However, the endothelium of lesional and nonlesional skin of all the 10 patients with diffuse or limited forms of the disease tested, expressed either decreased or undetectable amounts of MCP and DAF. CD59 expression was normal in some patients and lower than normal in others. Aberrant expression of MCP, DAF, or CD59 was not found in other control inflammatory, connective tissue and proliferative diseases studied.
CONCLUSIONS: In view of the common function of MCP and DAF to protect self cells from autologous C, their decrease or virtual absence from the endothelium of patients with SSc strongly suggests that this deficiency may contribute to vascular damage, resulting in intima proliferation and, finally, fibrosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7516986

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  9 in total

1.  Complement in acute and chronic arthritides: assessment of C3c, C9, and protectin (CD59) in synovial membrane.

Authors:  Y T Konttinen; A Ceponis; S Meri; A Vuorikoski; P Kortekangas; T Sorsa; A Sukura; S Santavirta
Journal:  Ann Rheum Dis       Date:  1996-12       Impact factor: 19.103

Review 2.  Vascular disease in scleroderma.

Authors:  Fredrick M Wigley
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

3.  Comparative proteomic analysis of serum from patients with systemic sclerosis and sclerodermatous GVHD. Evidence of defective function of factor H.

Authors:  Cinzia Scambi; Valentina La Verde; Lucia De Franceschi; Giovanni Barausse; Fabio Poli; Fabio Benedetti; Marco Sorio; Francesca Deriu; Paola Roncada; Oscar Bortolami; Francesco Turrini; Paola Caramaschi; Chiara Stranieri; Lisa M Bambara; Domenico Biasi
Journal:  PLoS One       Date:  2010-08-13       Impact factor: 3.240

4.  The local complement activation on vascular bed of patients with systemic sclerosis: a hypothesis-generating study.

Authors:  Cinzia Scambi; Sara Ugolini; T Sakari Jokiranta; Lucia De Franceschi; Oscar Bortolami; Valentina La Verde; Patrizia Guarini; Paola Caramaschi; Viviana Ravagnani; Guido Martignoni; Chiara Colato; Serena Pedron; Fabio Benedetti; Marco Sorio; Fabio Poli; Domenico Biasi
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

5.  Cartilage oligomeric matrix protein-induced complement activation in systemic sclerosis.

Authors:  Kaisa E Otteby; Emelie Holmquist; Tore Saxne; Dick Heinegård; Roger Hesselstrand; Anna M Blom
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

6.  Potential role of the lectin pathway of complement in the pathogenesis and disease manifestations of systemic sclerosis: a case-control and cohort study.

Authors:  Michael Osthoff; Gene-Siew Ngian; Melinda M Dean; Mandana Nikpour; Wendy Stevens; Susanna Proudman; Damon P Eisen; Joanne Sahhar
Journal:  Arthritis Res Ther       Date:  2014-11-18       Impact factor: 5.156

Review 7.  Beyond Systemic Lupus Erythematosus and Anti-Phospholipid Syndrome: The Relevance of Complement From Pathogenesis to Pregnancy Outcome in Other Systemic Rheumatologic Diseases.

Authors:  Silvia Cavalli; Paola Adele Lonati; Maria Gerosa; Roberto Caporali; Rolando Cimaz; Cecilia Beatrice Chighizola
Journal:  Front Pharmacol       Date:  2022-02-15       Impact factor: 5.810

8.  Increased Complement Activation in Systemic Sclerosis Patients with Skin and Lung Fibrosis.

Authors:  Chiara Pellicano; Marzia Miglionico; Laura Romaggioli; Amalia Colalillo; Lorenzo Vantaggio; Cecilia Napodano; Cinzia Callà; Francesca Gulli; Mariapaola Marino; Umberto Basile; Edoardo Rosato
Journal:  J Pers Med       Date:  2022-02-15

Review 9.  The role of decay accelerating factor in environmentally induced and idiopathic systemic autoimmune disease.

Authors:  Christopher B Toomey; David M Cauvi; Kenneth M Pollard
Journal:  Autoimmune Dis       Date:  2014-01-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.